NUMAB
Live / Registered — Registered (as of 23 Feb 2021)
What this means for you
Registered since 23 Feb 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79266778
- Registration number
- 6274672
- Mark type
- Stylized text
- Filed
- 28 Nov 2018
- Published for opposition
- 08 Dec 2020
- Registered
- 23 Feb 2021
Goods and services
- Class 001 — Chemicals: Chemicals, biochemicals, biological preparations and enzymes from biotechnological processes for use in industry and science; chemicals, biochemicals, biological preparations and enzymes, antibodies and antibody fragments, from biotechnological processes, for development and manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof; biological products comprising monoclonal antibodies and/or derivatives thereof, namely, antibodies and antibody fragments for use in laboratories, diagnosis and analysis for scientific and research purposes; chemical and biochemical additives, carriers and substances for manufacturing of pharmaceutical preparations and comprising monoclonal antibodies and/or derivatives thereof
- Class 005 — Pharmaceuticals: Pharmaceutical comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; pharmaceutical preparations comprising monoclonal antibodies and/or derivatives thereof for treatment of cancer, leukemia, lymphomas, inflammatory diseases, immunological diseases and other pathologies, treatable or improvable through use of antibodies that bind to, activate or block the target antigens; medicines comprising monoclonal antibodies and/or derivatives thereof for human medicine for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; medicines comprising monoclonal antibodies and/or derivatives thereof for veterinary use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical pharmaceutical products comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; diagnostic preparations for medical use comprising monoclonal antibodies and/or derivatives thereof; chemical preparations comprising monoclonal antibodies and/or derivatives thereof for pharmaceutical use for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases; chemical preparations for veterinary use comprising monoclonal antibodies and/or derivatives thereof for the treatment of cancer, leukemia, lymphomas, inflammatory diseases, and immunological diseases
- Class 042 — Scientific and technological services: Research and development services in the field of pharmaceutical preparations, biotechnology, antibodies and antibody fragments, proteins, micro-organisms and cells for therapeutic purposes; research services with respect to pharmaceutical preparations, biotechnology, antibody therapy and gene therapy; scientific and technological services of a chemical and molecular biological laboratory; research, product development and quality control services in the field of pharmacy, medical diagnostics and medical therapy; research services in the field of chemistry and biology; industrial analysis and research services in the field of pharmacy, medical diagnosis, and medical therapy; research and development services for antibody products for therapeutic purposes; conducting and preparing chemical, biochemical and biotechnological analysis and research
- Class 044 — Medical, beauty and agricultural services: Medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; medical services featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the fields of immuno-oncology, oncology and immunology; provision of medical information; Medical service featuring medicines comprising monoclonal antibodies and/or derivatives thereof in the nature of preparation and administration of medicines in the field of immuno-oncology, oncology and immunology; advice in connection with dietetics and nutrition; advice with respect to health and provision of health information in the fields of immuno-oncology, oncology and immunology; veterinary services featuring medicines comprising monoclonal antibodies and/or derivatives thereof; hygienic and beauty care for humans and animals; provision of information on diagnostic, prophylactic and therapeutic properties of drugs in the fields of immuno-oncology, oncology and immunology
Owner
- Numab Therapeutics AG, CH
- Numab Therapeutics AG, CH-8820 Wädenswil, CH
- Numab Therapeutics AG, CH-8820 Wädenswil, CH
- Numab Therapeutics AG, CH-8820 Wädenswil, CH
- Numab Innovation AG, CH
- Numab Therapeutics AG, CH
Prosecution history
- 23 Feb 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 31 Dec 2023 — NEW REPRESENTATIVE AT IB RECEIVED
- 27 Aug 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 13 Jun 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 06 Jun 2021 — CHANGE OF OWNER RECEIVED FROM IB
- 26 May 2021 — FINAL DISPOSITION NOTICE SENT TO IB
- 26 May 2021 — FINAL DISPOSITION PROCESSED
- 23 May 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Mar 2021 — CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 28 Feb 2021 — CORRECTION TRANSACTION RECEIVED FROM IB
- 23 Feb 2021 — REGISTERED-PRINCIPAL REGISTER
- 08 Dec 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Dec 2020 — PUBLISHED FOR OPPOSITION
- 06 Dec 2020 — NOTIFICATION PROCESSED BY IB
- 18 Nov 2020 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB